TP53 and CDKN2A Mutations Correlate with Survival, Stage, and Grade in Mesothelioma

被引：0
|
作者：
Zhu, Allen [1 ]
Husain, Aliya [1 ]
Hermina, Andrew [1 ]
Mueller, Jeffrey [2 ]
Kwon, Jung Woo [2 ]
机构：
[1] Univ Chicago, Chicago, IL USA
[2] Univ Chicago, Med Ctr, Chicago, IL USA
来源：
LABORATORY INVESTIGATION | 2024年 / 104卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
1592
引用
收藏
页码：S1972 / S1973
页数：2
相关论文
共 50 条
  • [41] LSC-2017-KRAS & TP53 mutations cause malignant mesothelioma
    Krontira, Anthi
    Marazioti, Antonia
    Vreka, Malamati
    Iliopoulou, Marianthi
    Lilis, Ioannis
    Giotopoulou, Georgia
    Spella, Magda
    Petrou, Helen
    Stathopoulos, Georgios
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [42] Integrative post-genome-wide association analysis of CDKN2A and TP53 SNPs and risk of esophageal adenocarcinoma
    Buas, Matthew F.
    Levine, David M.
    Makar, Karen W.
    Utsugi, Heidi
    Onstad, Lynn
    Li, Xiaohong
    Galipeau, Patricia C.
    Shaheen, Nicholas J.
    Hardie, Laura J.
    Romero, Yvonne
    Bernstein, Leslie
    Gammon, Marilie D.
    Casson, Alan G.
    Bird, Nigel C.
    Risch, Harvey A.
    Ye, Weimin
    Liu, Geoffrey
    Corley, Douglas A.
    Blount, Patricia L.
    Fitzgerald, Rebecca C.
    Whiteman, David C.
    Wu, Anna H.
    Reid, Brian J.
    Vaughan, Thomas L.
    CARCINOGENESIS, 2014, 35 (12) : 2740 - 2747
  • [43] Mass Spectrometry based Methylation Analysis of MDM2, CDKN2A, RB1, TP53 and TP73 and Associations to MDM2 Overexpression in Malignant Pleural mesothelioma
    Mairinger, F.
    Meier, S.
    Wessolly, M.
    Koehler, C.
    Wagner, F.
    Mairinger, E.
    Schmeller, J.
    Borchert, S.
    Wohlschlaeger, J.
    Ploenes, T.
    Hager, T.
    Rozynek, P.
    Kollmeier, J.
    Christoph, D.
    Schmid, K. W.
    Mairinger, T.
    Johnen, G.
    Walter, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 115 - 115
  • [44] CDKN2A和TP53基因在喉鳞状细胞癌中的突变
    李茂才
    雷大鹏
    Todorova TA
    Jordanov SH
    Stancheva GS
    中国医学文摘(耳鼻咽喉科学), 2014, 29 (05) : 319 - 319
  • [45] Mutation analysis of genes that control the G1/S cell cycle in melanoma: TP53, CDKN1A, CDKN2A, and CDKN2B
    José Luis Soto
    Carmen M Cabrera
    Salvio Serrano
    Miguel Ángel López-Nevot
    BMC Cancer, 5
  • [46] Clinical Features of Pediatric Acute Myeloid Leukemia with TP53 and CDKN2A/2B copy Number Alterations
    Hara, Yusuke
    Taki, Tomohiko
    Yamato, Genki
    Yoshida, Kenichi
    Shiozawa, Yusuke
    Shiba, Norio
    Kaburagi, Taeko
    Shiraishi, Yuichi
    Ohki, Kentaro
    Kawamura, Machiko
    Sotomatsu, Manabu
    Arakawa, Hirokazu
    Matsuo, Hidemasa
    Shimada, Akira
    Toki, Tsutomu
    Kiyokawa, Nobutaka
    Tomizawa, Daisuke
    Taga, Takashi
    Ito, Etsuro
    Horibe, Keizo
    Miyano, Satoru
    Ogawa, Seishi
    Adachi, Souichi
    Hayashi, Yasuhide
    BLOOD, 2019, 134
  • [47] Using CDKN2A loss in the context of wildtype TP53 to predict sensitivity for the MDM2 inhibitor milademetan.
    Tirunagaru, Vijaya G.
    Xu, Feng
    Hinz, Trista
    Heasley, Lynn
    Bryce, Richard
    Vellanki, Avanish
    Ku, Nora
    Doebele, Robert Charles
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [48] Clinical Effect of Driver Mutations of KRAS, CDKN2A/P16, TP53, and SMAD4 in Pancreatic Cancer: A Meta-Analysis
    Gu, Yujun
    Ji, Yayun
    Jiang, Hui
    Qiu, Ganbin
    GENETIC TESTING AND MOLECULAR BIOMARKERS, 2020, 24 (12) : 777 - 788
  • [49] The impact of CDKN2A mutations on overall survival in pancreatic adenocarcinoma
    Doyle, Allison
    Kubler, Manfred M.
    Harris, Ashton C.
    Lopez, Alfredo
    Govindaraj, Prateek
    Prins, Petra
    Weinberg, Benjamin Adam
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [50] CDKN2A and BAP1 germline mutations predispose to melanoma and mesothelioma
    Betti, M.
    Aspesi, A.
    Biasi, A.
    Casalone, E.
    Ferrante, D.
    Ogliara, P.
    Gironi, L. C.
    Giorgione, R.
    Farinelli, P.
    Grosso, F.
    Libener, R.
    Rosato, S.
    Turchetti, D.
    Maffe, A.
    Casadio, C.
    Ascoli, V.
    Dianzani, C.
    Colombo, E.
    Piccolini, E.
    Pavesi, M.
    Miccoli, S.
    Mirabelli, D.
    Bracco, C.
    Righi, L.
    Boldorini, R.
    Papotti, M.
    Matullo, G.
    Magnani, C.
    Pasini, B.
    Dianzani, I.
    CANCER LETTERS, 2016, 378 (02) : 120 - 130
12345